Amgen, AstraZeneca report positive phase 3 trial for Tezspire in EoE

Amgen and AstraZeneca have announced positive results from a Phase 3 trial of Tezspire, a biologic drug, for the treatment of eosinophilic esophagitis (EoE). The CROSSING trial, which enrolled 368 patients aged 12-80 with symptomatic and histologically active EoE, met its co-primary endpoints at week 24 and sustained them through week 52.

The trial measured histologic remission (peak esophageal eosinophil count of six or fewer eosinophils per high-power field) and improvement in dysphagia symptoms using the Dysphagia Symptom Questionnaire. The safety profile of Tezspire was consistent with its approved indications for severe asthma and chronic rhinosinusitis with nasal polyps.

EoE affects more than 470,000 people in the U.S., with prevalence increasing five-fold since 2009. Nearly half of patients do not achieve adequate disease control with current first-line treatments. Full trial results will be presented at an upcoming medical meeting and shared with regulatory authorities.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.